Trial Profile
β-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Corticosteroids; Methotrexate
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms Beta-SPECIFIC-4-Patients
- Sponsors Novartis
- 11 Aug 2020 Primary endpoint (Number of Participants in Clinical Remission on Canakinumab Who Are Able to Remain at an Initial Reduced Canakinumab Dose or Prolonged Canakinumab Dose Interval.) has been met.
- 11 Aug 2020 Results published in the Arthritis and Rheumatology
- 15 Jun 2019 Argentina, Hong Kong, Mexico and Peru were planned locations as per European Clinical Trials Database record.